Target intelligence / Profile preview

Solute carrier family 15 member 2 (PEPT2) (SLC15A2)

Target
SLC15A2
Molecular classification
Transporter, Solute carrier family, Major facilitator superfamily
01

Overview

Solute carrier family 15 member 2 (SLC15A2), commonly known as PEPT2, is a high-affinity, low-capacity proton-coupled transporter primarily responsible for the reabsorption of di- and tripeptides in the kidney. It is localized to the apical membrane of the renal proximal tubule and is also significantly expressed in the choroid plexus, lung, and mammary glands (UniProt, 1.4.3; Wikipedia, 1.4.5). In the brain, SLC15A2 plays a critical role in maintaining neuropeptide homeostasis by facilitating the efflux of peptide fragments from the cerebrospinal fluid (PubMed, 1.3.1). Beyond endogenous peptides, the transporter is a key determinant in the pharmacokinetics of various peptidomimetic drugs, including beta-lactam antibiotics, ACE inhibitors, and antiviral prodrugs (Guide to Pharmacology, 1.2.1). Genetic polymorphisms in SLC15A2, such as the PEPT2*2 variant, have been associated with altered susceptibility to environmental toxins like lead and may influence drug response (PubMed, 1.4.4). Its involvement in the transport of bacterial peptidoglycans also links it to innate immune responses via the NOD2 signaling pathway (MapMyGenome, 1.3.2). Consequently, SLC15A2 is a significant target for optimizing drug delivery and understanding inter-individual variability in drug disposition and toxicity.

Other names
PEPT2Peptide transporter 2Kidney-type H+/peptide cotransporterSolute carrier family 15 (H+/peptide transporter) member 2Oligopeptide transporter kidney isoform
02

Mechanism of action

Substrate for proton-coupled electrogenic symport, facilitating the uphill transport of di- and tripeptides across the plasma membrane driven by a proton gradient.

03

Biological functions

Peptide transportRenal reabsorptionBrain homeostasisInnate immune responseXenobiotic detoxification
04

Disease associations

Renal disorderNeurodegenerative diseaseLead neurotoxicityAsthmaMultiple sclerosis
05

Safety considerations

Drug-drug interactions (DDI) due to transporter competitionAltered drug pharmacokinetics in renal impairmentIncreased vulnerability to lead toxicity in specific genotypesPotential disruption of neuropeptide homeostasis in the CNS
06

Interacting drugs

Cefadroxil

9 more in the full profile.

07

Biomarkers

Renal clearance of peptide drugsCerebrospinal fluid neuropeptide levelsSLC15A2*2 polymorphismUrinary peptide excretion

Beyond the preview

Go deeper on Solute carrier family 15 member 2 (PEPT2) (SLC15A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 15 member 2 (PEPT2) (SLC15A2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call